Core Viewpoint - Zhejiang Jianfeng Group Co., Ltd. has announced the extension of a financial assistance loan provided to its wholly-owned subsidiary, Guizhou Huangping Jianfeng Cement Co., Ltd., to support the completion of relocation projects related to the raw material mining area [2][12]. Summary by Sections Financial Assistance Extension Overview - On August 18, 2023, Guizhou Jianfeng provided a loan of 23 million yuan to Huangping Urban Construction Investment Co., Ltd. for a two-year term, with 19.19 million yuan already repaid and a remaining balance of 3.81 million yuan to be extended for another two years without interest [2][3][12]. Details of the Borrower - Huangping Urban Construction Investment Co., Ltd. is a state-owned enterprise with a registered capital of 1.1 billion yuan, established on May 6, 2011, and has total assets of 2.373 billion yuan and a debt-to-asset ratio of 60.85% as of December 31, 2024 [4][5]. Board Meeting and Approval - The extension of the financial assistance was approved unanimously by the board of directors during the 11th meeting of the 12th session on August 15, 2025, with all nine directors present [12][15]. Cumulative Financial Assistance - After the extension, the total financial assistance provided to Huangping Urban Construction Investment Co., Ltd. amounts to 15.81 million yuan, representing 0.3% of the company's latest audited net assets, with no overdue amounts reported [13].

2024年1至12月份，尖峰集团的营业收入构成为：建材行业占比46.69%，医药行业占比32.79%，其它行 业占比9.15%，健康品行业占比5.88%，其他业务占比5.49%。 尖峰集团（SH 600668，收盘价：12.22元）8月15日晚间发布公告称，公司十二届11次董事会会议于 2025年8月15日以通讯表决的方式召开。会议审议了《关于子公司财务资助余额展期的议案》等文件。 （文章来源：每日经济新闻） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 证券简称：尖峰集团 证券代码：600668 编号：临 2025-040 浙江尖峰集团股份有限公司 关于子公司财务资助余额展期的公告 ● 主要内容：经浙江尖峰集团股份有限公司（以下简称"尖峰集团"或"本公 司"）十一届12次董事会批准，2023年8月18日，全资子公司贵州黄平尖峰水泥有 限公司（以下简称"贵州尖峰"）向黄平县城镇建设投资有限责任公司（以下简 称"黄平城投"）提供了2300万元借款，期限为两年。截至公告日，黄平城投已 归还1919.36万元，尚有余额380.64万元未归还，因涉及贵州尖峰原料矿区范围 内的相关搬迁工程尚未全部完工，拟同意前述380.64万元借款余额展期两年，该 展期借款不计利息。 ● 本次对外提供财务资助展期事项经本公司第十二届董事会第11次会议审议通 过，无需提交股东大会审议。 ● 本次财务资助展期金额较小，不会对公司的生产经营及资产状况产生重大不 良影响，不存在损害上市公司及股东利益的情形。 一、财务资助展期概况 因黄平城投负责 ...

一、董事会会议召开情况 （一）本次董事会会议的召集、召开符合有关法律、法规及《公司章程》的 相关规定。 （二）2025 年 08 月 15 日，本次董事会会议以通讯表决的方式召开。 （三）公司现有九名董事，全体董事出席了会议。 二、董事会会议审议情况 证券代码：600668 证券简称：尖峰集团 编号：临 2025-039 浙江尖峰集团股份有限公司 十二届11次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 详见《关于子公司财务资助余额展期的公告》（临 2025-040）。 三、相关附件 1、公司第十二届董事会第 11 次会议决议 特此公告 浙江尖峰集团股份有限公司 董事会 二〇二五年八月十六日 1 1、通过了《关于子公司财务资助余额展期的议案》 经审议与表决，董事会通过了《关于子公司财务资助余额展期的议案》，同 意全资子公司贵州黄平尖峰水泥有限公司向黄平县城镇建设投资有限责任公司 提供的借款余额380.64万元展期两年，该展期借款不计利息。 表决结果：9票同意、0票反对、0票弃权。 ...

（文章来源：证券日报） 证券日报网讯 8月13日晚间，尖峰集团发布公告称，近日，公司下属子公司安徽尖峰北卡药业有限公司 收到国家药品监督管理局关于化学原料药富马酸伏诺拉生的《化学原料药上市申请批准通知书》。 ...

Group 1 - Kaizhong Precision plans to invest up to 250 million yuan to establish a subsidiary and build a production base in Thailand, focusing on overseas connector and precision component business [1] - Longbo Technology reported a 60.18% year-on-year increase in net profit for the first half of 2025, with revenue of 122 million yuan, up 18.03% [2] - Dingyang Technology achieved a net profit of 76.88 million yuan in the first half of 2025, a year-on-year increase of 31.54%, with revenue of 279 million yuan, up 24.61% [4] Group 2 - Heng Rui Pharmaceutical received approval for clinical trials of two drugs, SHR-A2102 and Adebeli monoclonal antibody injection [6] - Maolai Optical plans to use up to 100 million yuan of idle funds for entrusted wealth management to improve fund utilization efficiency [8] - Shiji Information signed a major contract with MGM Grand, providing a next-generation cloud-based hotel information management system [7] Group 3 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 4 - Aolaide expects a net profit decrease of 68.41% to 72.77% for the first half of 2025, with revenue projected between 270 million and 290 million yuan [12] - Feilong Co. used 111 million yuan of idle funds for cash management through structured deposit products [13] - Anhui Construction won two major projects with a total investment exceeding 6.6 billion yuan [15] Group 5 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 6 - China Medical's subsidiary received approval for the listing of fumaric acid volnora raw materials [20] - Huayuan Vaccine's subsidiary received approval for clinical trials of Hib vaccine [29] - Ganfeng Lithium plans to integrate lithium salt lake projects in Argentina and provide financial support of up to 130 million USD [41]

关于子公司获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次安徽尖峰北卡药业有限公司获得化学原料药富马酸伏诺拉生的《化 学原料药上市申请批准通知书》，表明该原料药已符合国家相关原料药审评技术 标准，可在国内市场进行销售，有助于拓展子公司的业务领域。 风险提示：由于医药产品具有高科技、高风险、高附加值的特点，不仅 药品的前期研发及研制、报批到投产的周期长、投入大、环节多，而且药品的生 产和销售也容易受到国家政策、市场环境变化等因素影响，具有较大不确定性。 敬请广大投资者注意投资风险。 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的下属子公司安徽 尖峰北卡药业有限公司（以下简称"尖峰北卡"）收到国家药品监督管理局关于化 学原料药富马酸伏诺拉生的《化学原料药上市申请批准通知书》（通知书编号： 2025YS00694），现将相关情况公告如下： 一、化学原料药的基本情况 证券代码：600668 证券简称：尖峰集团 编号：临 2025-038 浙江尖峰集团股份有限公司 ...

Group 1 - The core point of the article is that Jianfeng Group's subsidiary, Anhui Jianfeng Beika Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Fumaric Acid Venlafaxine, which is used to treat gastroesophageal reflux disease as a potassium ion competitive acid blocker [1] Group 2 - Fumaric Acid Venlafaxine is specifically indicated for the treatment of gastroesophageal reflux disease [1] - The approval signifies a potential growth opportunity for Jianfeng Group in the pharmaceutical market [1]

Core Viewpoint - The announcement indicates that Jianfeng Group's subsidiary, Anhui Jianfeng Beika Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the chemical raw material drug Vonoprazan Fumarate, which is a potassium ion competitive acid blocker used for treating gastroesophageal reflux disease [1] Company Summary - Jianfeng Group's subsidiary, Anhui Jianfeng Beika, has obtained the "Chemical Raw Material Drug Listing Application Approval Notice" for Vonoprazan Fumarate, with the notice number 2025YS00694 [1] - The approval signifies that the raw material drug meets the national technical standards for raw material drug review, allowing it to be sold in the domestic market [1] - The company has the necessary production line in place for Vonoprazan Fumarate, which will help expand the subsidiary's business scope [1] Industry Summary - Vonoprazan Fumarate is developed by Takeda Pharmaceutical Company Limited and is used for the treatment of reflux esophagitis [1] - The approval of this drug aligns with the growing demand for effective treatments in the gastroenterology sector, indicating potential market opportunities [1]

Core Viewpoint - The announcement indicates that尖峰集团's subsidiary, 安徽尖峰北卡药业有限公司, has received approval from the National Medical Products Administration for the chemical raw material drug Vonoprazan Fumarate, which is a potassium ion competitive acid blocker used for treating gastroesophageal reflux disease [1] Group 1 - The approval notification number for the drug is 2025YS00694, confirming that the drug meets the national technical standards for chemical raw material drug review [1] - Vonoprazan Fumarate was developed by Takeda Pharmaceutical Company Limited in Japan [1] - The approval allows尖峰北卡 to sell the drug in the domestic market, which will help expand the subsidiary's business scope [1]